India’s First Dengue Vaccine Approved: Price, Dosage and Benefits Explained
India has approved its first dengue vaccine, QDENGA (TAK-003), developed by Takeda. The vaccine is approved for people aged 4 to 60 years and can be given regardless of previous dengue infection, without mandatory pre-vaccination testing.
Key details:
- Vaccine: QDENGA (TAK-003)
- Dosage: 2 doses, administered 3 months apart
- Age group: 4–60 years
- Protection: Designed to protect against all four dengue virus serotypes—DENV-1, DENV-2, DENV-3 and DENV-4.
- Previous dengue infection: The vaccine can be administered irrespective of previous dengue exposure.
- Price: The final retail price in India has not yet been officially announced; therefore, any circulating price estimates should be treated as provisional.
- Important: The vaccine reduces the risk of dengue but does not replace mosquito-control measures such as preventing mosquito breeding and avoiding mosquito bites.
This is a major milestone for India, but vaccination should be taken only after consulting a qualified healthcare professional, especially for children, pregnant individuals, and people with specific medical conditions.
